CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Patient-derived organoids as personalized avatars and a potential immunotherapy model in cervical cancer.
Patient-derived organoids as personalized avatars and a potential immunotherapy model in cervical cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
宫颈癌在发展中国家仍然是一个重要的健康问题。然而，找到一个能准确再现肿瘤特征的临床前模型具有挑战性。因此，我们建立了一个患者来源类器官（PDOs）生物样本库，包含67例异质性宫颈癌，其再现了原发肿瘤的组织病理学和基因组特征。类器官的体外反应表明其能够捕捉患者的影像学异质性。为了模拟个体对过继性T细胞疗法（ACT）的反应，我们在体外扩增了TIL（肿瘤浸润淋巴细胞）（TILs），并将其与配对的类器官共培养。PDOs-TILs共培养系统显示出明确的反应，与已建立的免疫治疗疗效标志物如CTLs比例相对应。本研究支持PDOs平台在宫颈癌前瞻性干预试验中指导治疗的潜力。
Cervical cancer remains a significant health issue in developing countries.
However, finding a preclinical model that accurately reproduces tumor characteristics is challenging.
Therefore, we established a patient-derived organoids (PDOs) biobank containing 67 cases of heterogeneous cervical cancer that mimic the histopathological and genomic characteristics of parental tumors. The in vitro response of the organoids indicated their ability to capture the radiological heterogeneity of the patients.
To model individual responses to adoptive T cell therapy (ACT), we expanded tumor-infiltrating lymphocytes (TILs) ex vivo and co-cultured them with paired organoids. The PDOs-TILs co-culture system demonstrates clear responses that correspond to established immunotherapy efficiency markers like the proportion of CTLs.
This study supports the potential of the PDOs platform to guide treatment in prospective interventional trials in cervical cancer.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
